Meeting
2012 ASCO Annual Meeting
A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents.
Authors
Guillermo Garcia-Manero
University of Texas M. D. Anderson Cancer Center, Houston, TX
Guillermo Garcia-Manero , Selina M. Luger , Stuart Goldberg , Jessica K. Altman , Martha Lucia Arellano , Meir Wetzler , Karen Seiter , Judy H. Chiao , Hagop Kantarjian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Citation
J Clin Oncol 30, 2012 (suppl; abstr 6520)
DOI
10.1200/jco.2012.30.15_suppl.6520
Abstract #
6520
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk myelodysplastic syndromes.
First Author: Ehab L. Atallah
Poster
2020 ASCO Virtual Scientific Program
A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies.
First Author: Maro Ohanian
Poster
2018 ASCO Annual Meeting
CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS.
First Author: Eric Huselton
Poster
2017 ASCO Annual Meeting
A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients with metastatic melanoma (MM).
First Author: Emily Keung